Preclinical studies have shown that EGFR activation can upregulate the expression of endogenous PD-L1 on tumor cells, thus inducing apoptosis of T cells and promoting immune evasion of EGFR-mutant NSCLC (17). The gene discussed is EGFR; the disease is neoplasm.